StockNews.AI
CGEN
StockNews.AI
4 hrs

Compugen to Present at SITC 2025

1. Compugen announces first-in-human trial for anti-IL18BP antibody, COM503. 2. Trial to be presented at SITC, November 7-9, 2025. 3. COM503 is a potential first-in-class therapy for solid malignancies. 4. Compugen's pipeline includes other promising candidates in immunotherapy. 5. The company's shares are traded on Nasdaq as CGEN.

5m saved
Insight
Article

FAQ

Why Bullish?

The successful presentation at SITC could boost investor interest in CGEN, following positive historical examples where clinical trial announcements led to stock price increases.

How important is it?

The article discusses a major trial that could showcase CGEN's therapeutic potential, making it highly relevant for investors.

Why Long Term?

The trial results and subsequent updates over the coming years could significantly enhance CGEN's long-term valuation.

Related Companies

GILDAZN
, /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery, powered by AI/ML today announced, that a trial in progress of the first in human clinical trial to assess the anti-IL18BP antibody, COM503 (GS-0321) in participants with advanced solid malignancies will be presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place between November 7-9, 2025, in National Harbor, Maryland. Poster presentation details: Abstract Title: A First in human clinical trial to assess the anti-IL18BP antibody, COM503 (GS-0321) in Participants with Advanced Solid MalignanciesAbstract number: 589Presenter: Dr. Manish Sharma, MD, Co-Director of Clinical Research, START Midwest, Grand RapidsDate: Friday, November 7, 2025 About CompugenCompugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive AI/ML powered computational discovery platform (Unigen™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development, is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address new mechanisms to activate the immune system against cancer. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. Company contact:Yvonne Naughton, Ph.D.Vice President, Head of Investor Relations and Corporate CommunicationsEmail: [email protected]Tel: +1 (628) 241-0071  SOURCE Compugen Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News